Position in ALKS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,306,338
+$374,255 QoQ
Shares Held
101,266
-27.4% QoQ
Ownership
0.060%
of shares outstanding
% of Portfolio
1.08%
of 13F equity value
Holder Rank
#121
of 423 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026DAFNA Capital Management LLC holds $22,367,669 across 6 Drug Manufacturers - Specialty & Generic names. ALKS ranks #2 (23.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
57,769 | $9,736,387 | |
| 2 | ALKS |
Alkermes plc.
This page
|
101,266 | $5,306,338 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
400,248 | $4,002,480 | |
| 4 | AQST |
Aquestive Therapeutics, Inc.
|
645,915 | $2,687,006 | |
| 5 | SCYX |
Scynexis Inc
|
135,868 | $552,982 | |
| 6 | ADCT |
ADC Therapeutics SA
|
77,081 | $82,476 |
All Filings in ALKS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,306,338 | 101,266 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $4,932,083 | 139,482 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,644,339 | 130,248 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $4,042,440 | 134,748 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,968,230 | 103,748 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,110,484 | 94,200 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,471,332 | 120,700 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $3,378,393 | 120,700 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,908,870 | 120,700 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||